Trial Profile
Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Dec 2017 Status changed from active, no longer recruiting to completed.
- 16 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
- 16 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.